Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARQT Arcutis Biotherapeutics Inc.

未开盘 08-19 16:00:00 EDT

26.46

-0.08

-0.30%

盘后26.35

-0.11-0.42%

19:30 EDT

最高27.19	最低26.37	成交量102.54万
今开27.00	昨收26.54	日振幅3.09%
总市值33.09亿	流通市值29.42亿	总股本1.25亿
成交额2,728万	换手率0.92%	流通股本1.11亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":26.46,"timestamp":1787169600000,"preClose":26.54,"halted":0,"volume":1025411,"hourTrading":{"tag":"盘后","latestPrice":26.35,"preClose":26.46,"latestTime":"19:30 EDT","volume":104551,"amount":2769207.2882,"timestamp":1787182206404,"change":-0.11,"changeRate":-0.004157,"amplitude":0.004157},"delay":0,"changeRate":-0.003014318010550049,"floatShares":111176161,"shares":125073249,"eps":0.215414,"marketStatus":"未开盘","change":-0.08,"latestTime":"08-19 16:00:00 EDT","open":27,"high":27.19,"low":26.37,"amount":27283486.802837,"amplitude":0.030897,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.215414,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787212800000},"marketStatusCode":0,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":26.54,"preHourTrading":{"tag":"盘前","latestPrice":27,"preClose":26.54,"latestTime":"09:28 EDT","volume":1960,"amount":52262.23184,"timestamp":1787146111073,"change":0.46,"changeRate":0.017332,"amplitude":0.016956},"postHourTrading":{"tag":"盘后","latestPrice":26.35,"preClose":26.46,"latestTime":"19:30 EDT","volume":104551,"amount":2769207.2882,"timestamp":1787182206404,"change":-0.11,"changeRate":-0.004157,"amplitude":0.004157},"volumeRatio":0.678046,"impliedVol":0.4215,"impliedVolPercentile":0.1633},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"1125740022","title":"Arcutis Biotherapeutics 上调2026全年净产品销售额指引：从4.8亿-4.95亿美元提升至5.25亿-5.4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125740022","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125740022?lang=zh_cn&edition=full","pubTime":"2026-08-06 04:04","pubTimestamp":1785960252,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. 今日宣布，已正式上调其2026全年的净产品销售额预期。相较于此前设定的4.8亿至4.95亿美元区间，该公司现预计这一数字将攀升至5.25亿至5.4亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101101203","title":"FDA受理Arcutis旗下Zoryve®（罗氟司特）乳膏0.05%补充新药申请，用于治疗低至3月龄婴儿的轻中度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1101101203","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101101203?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512078,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Arcutis Biotherapeutics Inc. (ARQT) 旗下产品Zoryve®（罗氟司特）乳膏0.05%的补充新药申请。该申请旨在扩展该药物的适应症，用于治疗年龄低至3个月婴儿的轻中度特应性皮炎。这一进展标志着该疗法在满足年幼患者群体未竟医疗需求的道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167416883","title":"Arcutis Biotherapeutics：FDA为Zoryve乳膏0.05% sNDA设定2027年2月23日PDUFA目标行动日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1167416883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167416883?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512075,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics公司宣布，美国食品药品监督管理局已为其Zoryve乳膏0.05%的补充新药申请设定了处方药使用者付费法案目标行动日期，定于2027年2月23日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193550139","title":"FDA批准Arcutis旗下Zoryve®（罗氟司特）乳膏0.3%用于治疗低至2岁儿童的斑块状银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1193550139","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193550139?lang=zh_cn&edition=full","pubTime":"2026-06-30 07:07","pubTimestamp":1782774434,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准Arcutis Biotherapeutics Inc.旗下产品Zoryve®（罗氟司特）乳膏0.3%用于治疗斑块状银屑病，其适用患者年龄范围扩展至最低两岁的儿童。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180888150","title":"Arcutis Biotherapeutics依据纳斯达克上市规则5635(C)(4)报告激励性股权授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1180888150","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180888150?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:19","pubTimestamp":1778271584,"startTime":"0","endTime":"0","summary":"生物制药公司Arcutis Biotherapeutics Inc.宣布，其已根据纳斯达克股票市场的上市规则5635(C)(4)条款，完成了新一轮激励性股权授予。该规则主要适用于新入职员工，允许公司在不经过股东批准的情况下授予股权激励，旨在吸引和留住关键人才。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131553441","title":"Arcutis向FDA提交Zoryve®乳膏补充新药申请 拟将特应性皮炎适应症扩展至3个月大婴儿","url":"https://stock-news.laohu8.com/highlight/detail?id=1131553441","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131553441?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:05","pubTimestamp":1777291534,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 已向美国食品药品监督管理局（FDA）提交了一份补充新药申请（sNDA），旨在将其产品Zoryve®（罗氟司特）0.05%乳膏的适应症范围扩大，用于治疗低至3个月婴儿的特应性皮炎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175483042","title":"Arcutis旗下Zoryve®（罗氟司特）乳膏获美国皮肤病学会首个儿童特应性皮炎指南强力推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1175483042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175483042?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:03","pubTimestamp":1776859424,"startTime":"0","endTime":"0","summary":"在最新发布的美国皮肤病学会（AAD）首部儿童特应性皮炎临床指南中，Arcutis Biotherapeutics Inc. (ARQT) 旗下的Zoryve®（罗氟司特）乳膏获得了强烈推荐。这一历史性指南的认可，标志着该疗法在儿科皮肤病治疗领域的重要地位得到确立。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197315235","title":"Arcutis公布Zoryve®（罗氟司特）乳膏0.05%治疗2至5岁儿童轻中度特应性皮炎长期积极安全性和有效性数据发表于《儿科皮肤病学》","url":"https://stock-news.laohu8.com/highlight/detail?id=1197315235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197315235?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:06","pubTimestamp":1773147980,"startTime":"0","endTime":"0","summary":"生物制药公司Arcutis Biotherapeutics Inc.宣布，其Zoryve®（罗氟司特）乳膏0.05%用于治疗2至5岁儿童轻中度特应性皮炎的长期积极安全性和有效性数据，已在权威医学期刊《儿科皮肤病学》上正式发表。\n该研究数据证实，Zoryve®乳膏在此低龄患者群体中展现出持久的疗效和良好的耐受性，为儿科特应性皮炎的治疗提供了新的重要循证依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197207844","title":"Arcutis启动Arq-234一期1a/1b研究入组，评估CD200R激动剂在健康志愿者及特应性皮炎成人患者中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1197207844","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197207844?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:06","pubTimestamp":1772543187,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 已正式启动其候选药物Arq-234的一期1a/1b临床研究，并开始招募受试者。该项研究旨在评估这款CD200R激动剂在健康志愿者以及患有特应性皮炎的成人群体中的安全性与耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355756","title":"Arcutis Biotherapeutics, Inc.2025财年实现净利润-16.14百万美元，同比增加88.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616355756?lang=zh_cn&edition=full","pubTime":"2026-03-02 00:00","pubTimestamp":1772380845,"startTime":"0","endTime":"0","summary":"3月2日，Arcutis Biotherapeutics, Inc.公布财报，公告显示公司2025财年净利润为-16.14百万美元，同比增加88.47%；其中营业收入为3.76亿美元，同比增加90.86%，每股基本收益为-0.13美元。从资产负债表来看，Arcutis Biotherapeutics, Inc.总负债2.43亿美元，其中短期债务1000000.00美元，资产负债比为1.79，流动比率为3.17。机构评级：截至2026年3月2日，当前有8家机构对Arcutis Biotherapeutics, Inc.目标价做出预测，其中目标均价为34.75美元，其中最低目标价为33.00美元，最高目标价为36.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302000054a43e8c0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302000054a43e8c0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517524988","title":"Arcutis Biotherapeutics, Inc.盘中异动 下午盘急速拉升5.22%报13.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517524988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517524988?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:56","pubTimestamp":1741114573,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日02时56分，Arcutis Biotherapeutics, Inc.股票出现波动，股价快速上涨5.22%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1293.93%、1186.20%、1169.09%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Celularity Inc C/Wts 16/07/2026 ，振幅分别为122.48%、68.89%、66.02%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030502561396398385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030502561396398385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630861","title":"Arcutis Biotherapeutics, Inc.盘中异动 大幅下跌5.04%报13.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516630861?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:08","pubTimestamp":1741014524,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时08分，Arcutis Biotherapeutics, Inc.股票出现波动，股价大幅下挫5.04%。截至发稿，该股报13.00美元/股，成交量42.1476万股，换手率0.36%，振幅6.28%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1220.90%、127.04%、104.27%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230844989a1a89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230844989a1a89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516312557","title":"Arcutis Biotherapeutics, Inc.2024财年实现净利润-1.40亿美元，同比增加46.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516312557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516312557?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844864,"startTime":"0","endTime":"0","summary":"3月2日，Arcutis Biotherapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.40亿美元，同比增加46.56%；其中营业收入为1.97亿美元，同比增加230.48%，每股基本收益为-1.16美元。从资产负债表来看，Arcutis Biotherapeutics, Inc.总负债1.91亿美元，其中短期债务820000.00美元，资产负债比为1.83，流动比率为0.05。机构评级：截至2025年3月2日，当前有7家机构对Arcutis Biotherapeutics, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为15.00美元，最高目标价为29.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000132abe2c5b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000132abe2c5b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301367","title":"Arcutis Biotherapeutics, Inc.盘中异动 股价大涨5.08%报13.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301367","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516301367?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:46","pubTimestamp":1740775606,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时46分，Arcutis Biotherapeutics, Inc.股票出现异动，股价快速拉升5.08%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3285.97%、607.09%、401.71%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.90%、48.19%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010446469896c6aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010446469896c6aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514333380","title":"高盛：维持Arcutis Biotherapeutics(ARQT.US)评级，由中性调整至中性评级, 目标价由13.00美元调整至15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333380","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514333380?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:41","pubTimestamp":1740674501,"startTime":"0","endTime":"0","summary":"高盛：维持Arcutis Biotherapeutics(ARQT.US)评级，由中性调整至中性评级, 目标价由13.00美元调整至15.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28004148440835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857342","title":"瑞穗银行：维持Arcutis Biotherapeutics(ARQT.US)评级，由优于大市调整至优于大市评级, 目标价由20.00美元调整至21.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857342","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514857342?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Arcutis Biotherapeutics(ARQT.US)评级，由优于大市调整至优于大市评级, 目标价由20.00美元调整至21.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161121","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856805","title":"Arcutis Biotherapeutics, Inc.股价上涨10.20% 市值涨1.63亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856805?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580329,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Arcutis Biotherapeutics, Inc.股票出现异动，股价快速拉升10.20%。截至发稿，该股报13.45美元/股，成交量13.6755万股，换手率0.12%，振幅6.56%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2782.30%、115.75%、90.27%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为28.81%、16.85%、14.35%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223209a254f693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223209a254f693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156921339","title":"异动解读 | 亿万销售创新高,Arcutis Biotherapeutics盘前大涨9.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156921339","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156921339?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:48","pubTimestamp":1740566920,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.于今日盘前大涨9.18%,引发市场广泛关注。此前,该公司发布了2024年第四季度财报,数据显示其销售额达到7140万美元,同比大涨427.87%,远超市场普遍预期。与销售业绩一致,Arcutis第四季度每股亏损仅为0.09美元,远低于分析师预期的0.24美元亏损。出色的业绩数据令投资者对公司未来发展充满信心,推动盘前股价大幅飙升。作为一家专注皮肤疾病创新治疗的生物科技公司,Arcutis近期的表现无疑为其在行业内赢得一席之地,并吸引更多投资者关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154950948","title":"异动解读 | Arcutis Biotherapeutics公司去年第四季度业绩大增,股价盘后大涨9.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154950948","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154950948?lang=zh_cn&edition=full","pubTime":"2025-02-26 09:17","pubTimestamp":1740532644,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics公司于盘后大涨9.02%,引起了市场广泛关注。财报显示,Arcutis去年第四季度每股亏损仅为0.09美元,而分析师此前预期为0.24美元。较上年同期亏损0.72美元,亏损幅度大幅收窄。值得注意的是,公司2024年第四季度销售额达到7140万美元,较上年同期增长427.87%,远超市场普遍预期的6016万美元。作为一家专注于开发创新药物治疗皮肤疾病的生物技术公司,Arcutis Biotherapeutics出色的销售数据证明了其产品在市场上备受青睐,未来发展潜力值得期待。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110411586","title":"异动解读 | Arcutis Biotherapeutics盘后大涨8.36%,2024年Q4财报亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1110411586","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110411586?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:33","pubTimestamp":1740519237,"startTime":"0","endTime":"0","summary":"生物技术公司Arcutis Biotherapeutics昨日盘后大涨8.36%,引发市场关注。公司于当日公布了2024年第四季度财报,业绩表现出色或是导致股价上涨的主要原因。财报显示,Arcutis Biotherapeutics去年第四季度每股亏损仅为0.09美元,优于分析师平均预期亏损0.24美元。与去年同期相比,亏损幅度显著收窄。作为一家专注于发现、开发和商业化治疗皮肤病学疾病的创新药物的公司,Arcutis Biotherapeutics的业绩表现令市场投资者重拾信心。若公司能够持续保持良好的销售增长势头,股价有望进一步走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Arcutis Biotherapeutics盘后大涨8.36%,2024年Q4财报亮眼","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com;investors.arcutis.com","stockEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.0389},{"period":"3month","weight":0.2594},{"period":"6month","weight":0.0411},{"period":"1year","weight":0.6779},{"period":"ytd","weight":-0.0888}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcutis Biotherapeutics, Inc.前身是根据特拉华州法律于2016年6月成立的，名称为Arcutis，Inc.，后将名称更改为Arcutis Biotherapeutics，Inc.。该公司是一家后期生物制药公司，致力于针对医疗需求未得到满足的皮肤病开发和商业化治疗。该公司目前的产品组合包括局部治疗，具有潜在的潜力，可以解决免疫介导的皮肤病和疾病或免疫皮肤病。该公司的策略是针对皮肤病学中经过验证的生物学目标识别和开发治疗方法，以提供差异化的临床特征，从而解决现有疗法在目标适应症方面的主要缺点。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.076618},{"month":2,"riseRate":0.857143,"avgChangeRate":0.210567},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.041444},{"month":4,"riseRate":0.428571,"avgChangeRate":0.034314},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.100595},{"month":6,"riseRate":0.857143,"avgChangeRate":0.090855},{"month":7,"riseRate":0.714286,"avgChangeRate":0.024031},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.018567},{"month":9,"riseRate":0.5,"avgChangeRate":-0.050429},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.153171}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}